StockWatch
·

LINCOLN PHARMACEUTICALS LTD. Q2 FY27 Results

LINCOLNQ2 FY27 Results
Filing
Result:Weak· Market: Crashed#Margin squeeze#Base effect
MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue191.357.9%17.1%
Total Income200.880.3%17.8%
Expenditure171.8611.6%21.2%
PBT29.0239.0%0.7%
Net Profit20.4343.6%2.2%
OPM12.38%3.09pp3.19pp
NPM10.17%7.81pp1.54pp
EPS10.2043.6%2.2%
View full financials

Pharma core metric is adjusted PAT growth, and at just +2.2% YoY on PBT that barely moved and OPM/NPM compressing sharply (12.4% vs 15.6%, 10.2% vs 11.7%), profit growth essentially stalled while costs outran revenue, which is below-par quality for the sector despite healthy top-line growth.

Q2 FY-2027 RESULTS · LINCOLN

Lincoln Pharma Q2 FY27: PAT up 2% YoY as margins compress, revenue +17%

PAT +2.21% YoY · revenue +17.13% · margins compressing

29 Oct 2026 · 3 min read
Revenue

₹191.35 Cr

+17.13% YoY

PAT (consolidated)

₹20.43 Cr

+2.21% YoY

Net margin

10.17%

-1.5pp YoY

EPS

₹10.2

Lincoln Pharmaceuticals reported consolidated (and effectively identical standalone) revenue from operations of ₹191.35 Cr for Q2 FY27, up 17.1% YoY from ₹163.36 Cr and up 7.9% QoQ from ₹177.28 Cr in Q1 FY27. Profit did not keep pace: consolidated PAT was ₹20.43 Cr, up just 2.2% YoY from ₹19.98 Cr, and down 43.6% QoQ from ₹36.23 Cr in Q1 FY27. EPS was ₹10.20 against ₹9.98 a year earlier. Neither period carried exceptional items, so this is a clean like-for-like reported comparison, not a one-off distortion.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹191.35 Cr+7.9%+17.1%
Expenses₹171.86 Cr+11.6%+21.2%
PAT₹20.43 Cr-43.63%+2.21%
Net margin10.17%-7.8pp-1.5pp
EPS₹10.2-43.6%+2.2%

The gap between revenue and profit growth shows up in margins. Operating margin (PBT + finance cost + depreciation, less other income, over revenue from operations) fell to roughly 12.4% from about 15.5% both a year ago and last quarter, while net profit margin on total income slipped to 10.2% from 17.98% in Q1 FY27 and 11.71% in Q2 FY26. Total expenses rose faster than income this quarter, with cost of materials consumed the single largest line at ₹77.47 Cr. Tax of ₹8.59 Cr included a ₹1.74 Cr short provision for prior years, a modest additional drag on reported PAT but not the main story — the main story is expense growth outrunning revenue growth.

₹
492.14532.85573.55614.25654.96511.907-2708-1809-0910-0510-2810-29Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹511.9, down 12% over the past month of trading.

₹ Cr
013.5327.0640.5827.68Q1 FY26rev ₹154 Cr19.98Q2 FY26rev ₹163 Cr28.6Q3 FY26rev ₹166 Cr11.63Q4 FY26rev ₹187 Cr36.23Q1 FY27rev ₹177 Cr20.43Q2 FY27rev ₹191 Cr
Quarterly consolidated PAT, ₹ Crore

No street estimates could be found for this print: a pre-result preview explicitly noted that no analyst consensus for Lincoln Pharma's Q2 FY27 was in the public domain, so vsStreet is unknown rather than inferred. The company also has no formal prior guidance on record for this specific quarter, so the print cannot be graded against a stated target; alongside results it reiterated a three-year ambition of ₹1,000 Cr revenue at 15-18% annual growth led by cardiac, diabetic, dermatology and ENT segments — a forward target, not a backward-looking guidance score. During the quarter the company launched four new domestic divisions and commissioned an API facility at its Khatraj plant, closed its trading window ahead of results, saw its senior QA General Manager resign (with a replacement appointed the same week), held its 32nd AGM approving an FY26 final dividend of ₹1.80/share, and saw FII holding rise to 4.55% as of September 30, 2026 — none of which directly explains the margin compression, which traces to the expense-side numbers above.

  • W1

    Whether operating margin recovers toward the ~15.5% run-rate seen in Q1 FY27 and Q2 FY26, or Q2 FY27's ~12.4% is the new baseline.

  • W2

    Progress on the ₹1,000 Cr/15-18% annual growth target management reiterated this quarter — track H2 FY27 revenue against H1 FY27's ₹402.43 Cr.

  • W3

    Whether the four new domestic divisions and the Khatraj API facility commissioned this quarter begin contributing to revenue and margin in H2 FY27.

Consolidated and standalone are numerically identical this quarter — subsidiary Zullinc Healthcare LLP (total assets ₹140.53 Lakh) contributed nil income/profit per the auditor's review note; no exceptional items in either period.

Informational and educational content only. Not investment advice.